Claire kept the receiver against her ear several seconds after the call ended.
Daniel saw her face and stood immediately.
“What did he say?”
Claire lowered the phone.
“He told us to stop the chemotherapy.”
Dr. Shah moved closer. “Who?”
“I don’t know.”
“What exactly did he say?”
“If I want Sophie to survive what happens next, stop the chemotherapy. We have three days.”
Nobody spoke.
The chemotherapy pump continued its slow electronic rhythm beside Sophie’s bed.
Sophie stared at it.
“Is that thing killing me?”
“No,” Dr. Shah said.
The answer came so quickly that Sophie relaxed slightly.
Then Shah added, “But we need to understand why somebody wants us to stop it.”
Daniel turned toward Agent Bell’s voice still coming through the speakerphone from Facility 17.
“Did you hear that?”
“Yes.”
“Trace the hospital call.”
“Already happening.”
Eric stepped toward the window.
“Three days matches the procedure date.”
Claire nodded.
“That can’t be coincidence.”
Sophie looked between them.
“So the bad people want me alive for whatever they planned.”
No one corrected the phrase bad people.
At the moment, precision did not improve it.
Dr. Shah unplugged neither drug nor line.
Instead, she checked the infusion label, dose, and remaining time herself.
Claire watched her.
“You’re continuing?”
“For now.”
“What if the caller is telling the truth?”
“What if he wants us to interrupt the most effective treatment we currently have?”
Claire hated both possibilities.
Daniel pointed toward Sophie.
“Can you test whether the chemotherapy is interacting with the engineered receptor?”
“Yes.”
“How fast?”
“We already started.”
“Then nobody changes anything until we know.”
Dr. Shah nodded.
“That is my recommendation.”
Claire looked at Sophie.
Sophie shrugged weakly.
“Okay.”
That small acceptance hurt more than panic would have.
A ten-year-old should not have been required to decide whether strangers manipulating her biology were more dangerous than cancer drugs.
Agent Bell’s team recovered additional files at Facility 17 overnight.
Most were encrypted.
One was not.
A procedural checklist titled RESURRECTION PHASE II included no patient names, only subject identifiers.
S.H.-10 appeared repeatedly.
The procedure was not scheduled at Facility 17.
Its location field contained a six-character code.
Eric recognized the format.
“That’s a NorthStar distribution-site identifier.”
Bell asked which location.
Eric searched through an old corporate directory from his laptop.
The code belonged to a warehouse facility outside Millhaven, nearly two hundred miles away.
“What do they distribute?” Daniel asked.
“Officially? Temperature-controlled biological products.”
“Unofficially?”
Eric gave him a tired look.
“At this point, I’m afraid to guess.”
Federal agents were dispatched.
By morning, surveillance showed the facility was active.
Employees arrived normally.
Trucks moved through loading bays.
Nothing about it looked like a secret laboratory.
“That’s how NorthStar operates,” Eric said. “Legitimate business wrapped around whatever else is happening.”
Claire sat beside Sophie while he spoke.
“Could a medical procedure happen there?”
“Not in the warehouse I remember.”
“Then why the code?”
Eric stared at the file.
“Maybe the code isn’t a place.”
Agent Bell considered that.
“What else could it identify?”
“A shipment.”
The room went still.
Eric stood and began typing.
NorthStar shipment identifiers began with facility codes followed by route dates.
The six-character entry in Sophie’s file could correspond to a distribution origin rather than the final destination.
“So something is being shipped,” Claire said.
Eric nodded.
“Probably for Sophie.”
The idea was somehow worse.
Dr. Shah entered carrying preliminary laboratory data.
“We found evidence that Sophie’s tumor cells respond differently to one component of her current chemotherapy.”
Claire’s stomach tightened.
“Differently how?”
“The engineered receptor appears to activate a survival pathway when exposed to it.”
Daniel frowned.
“You mean the chemotherapy makes the cancer stronger?”
“Not exactly. The drug still damages tumor cells, but cells with high receptor expression appear better able to recover.”
Claire stared at the infusion pump.
“Then stop it.”
Dr. Shah nodded.
“We are stopping that component.”
A nurse entered.
Within minutes, the medication was discontinued.
Sophie watched the tubing.
“So the creepy caller was right?”
“Partly,” Shah said.
Sophie frowned.
“I hate when creepy people are right.”
Daniel rubbed her shoulder.
“Same.”
The rest of Sophie’s treatment would continue with modifications.
Dr. Shah explained that they were replacing the problematic agent rather than stopping chemotherapy entirely.
Claire understood only the essential point.
Somebody had known Sophie’s tumor biology before her own doctors did.
That meant the caller had access to research data not found at Facility 17.
“Samuel,” Claire said.
Eric shook his head.
“That wasn’t his voice.”
“He could have used someone.”
“Maybe.”
“But?”
Eric stared at the floor.
“My father called to warn us about SV-2A. He could have told us to stop chemo then.”
Daniel nodded slowly.
“Instead somebody waited until after the drug was already running.”
Claire felt the implication settle.
“They wanted to see what happened.”
Dr. Shah looked at them.
“That is possible.”
Agent Bell returned to the hospital shortly after noon.
He brought photographs from the hidden level of Facility 17.
One wall contained a timeline.
Not Sophie’s entire life.
Specific biological milestones.
Birth.
Vector administration.
First documented hormone shift.
Puberty onset.
Brightwell injection.
First headache report.
Positive hCG.
Tumor confirmation.
Chemotherapy initiation.
The last entry had been added automatically.
CHEMOTHERAPY RESPONSE: INCOMPLETE DATA.
Daniel stared at it.
“They really were watching.”
Bell nodded.
“Until we cut the feed.”
“What happens when they lose data?” Eric asked.
“We’re hoping they make a mistake trying to restore access.”
Claire looked at the timeline.
Beside each milestone was a code.
Most meant nothing to her.
One appeared repeatedly.
M1.
Bell had not yet identified it.
Eric stared at the code.
“Maya.”
Claire looked at him.
“What?”
“M1. Maya One.”
No one answered.
He pointed at Sophie’s identifier.
S.H.-10.
“Ten could mean tenth-year endpoint.”
Dr. Shah shook her head.
“Or protocol version ten.”
“Maybe.”
Sophie looked up.
“Or I was the tenth kid.”
Everyone turned toward her.
Bell’s expression changed.
“Why do you say that?”
“Because there were other names in the computer.”
Claire remembered Generation Two.
Maya.
Sophie.
But Facility 17 had contained records for nearly two hundred children.
Bell pulled up a database list.
Subject codes.
S.H.-01.
S.H.-02.
S.H.-03.
All the way through S.H.-10.
Claire’s chest tightened.
“There were nine before Sophie?”
Bell began opening records.
S.H.-01 was Maya Hale.
Eric went pale.
“That makes no sense. Maya should be M1.”
“Unless S.H. doesn’t mean Sophie Hale,” Claire said.
Dr. Shah looked at the screen.
“Samuel Hale.”
Bell nodded.
Samuel Hale subject series.
Maya was first.
Eight others followed.
Sophie was tenth.
“Were they all related to him?” Claire asked.
“No.”
Bell opened files.
The second subject was male.
The third was female.
Different surnames.
Different states.
Different hospitals.
All had rare inherited cancer-risk variants.
All received versions of Samuel’s vectors during infancy or early childhood.
Claire’s hands began shaking.
“How many survived?”
Bell stopped scrolling.
Three were alive.
Two had died from unrelated causes.
Four had developed cancers associated with abnormal endocrine activation.
Maya had died after delayed treatment.
One boy had died during an experimental intervention.
Another girl disappeared from medical records at age thirteen.
Sophie was the youngest active subject.
Dr. Shah looked horrified.
“This wasn’t a family experiment anymore.”
Eric shook his head.
“No. It became a platform.”
Samuel had begun with his own bloodline.
Then somebody expanded the work.
NorthStar supplied logistics.
False clinics provided access.
School screenings identified candidates.
Medical records were altered or erased.
Children became subjects without knowing they were enrolled.
Claire stared at Sophie.
“Why did he keep calling it the Hale line?”
Eric answered.
“Because my father started it.”
Agent Bell’s phone rang.
He answered.
The team at Millhaven had identified a shipment connected to Sophie’s procedure code.
A refrigerated container had left the facility that morning.
Destination: their city.
Claire’s pulse jumped.
“What’s inside?”
“Documentation says cellular therapy material.”
Dr. Shah stepped forward.
“For which hospital?”
Bell looked at her.
“Yours.”
The room went quiet.
“Our hospital ordered it?”
“Someone did.”
Dr. Shah called pharmacy administration.
No order existed.
No approved cellular therapy had been requested for Sophie.
The shipment was fraudulently directed to the hospital.
“When does it arrive?” Daniel asked.
Bell checked.
“Tomorrow morning.”
Sophie frowned.
“They mailed my mystery treatment?”
Claire almost laughed from the absurdity.
Bell did not.
“We’re intercepting it before delivery.”
“No,” Eric said.
Everyone looked at him.
Bell’s eyes narrowed.
“Explain.”
“If you intercept it now, whoever is expecting confirmation knows we found it.”
Daniel stared at him.
“You want it delivered?”
“To a controlled receiving area.”
Bell considered it.
Claire did not like how quickly the idea made sense.
“Use it to see who comes for it.”
Bell nodded slowly.
“That may be useful.”
Daniel looked at Claire.
“We are using a fake delivery to trap people in the hospital where Sophie is.”
Bell answered before Claire could.
“They will never get near this floor.”
“You said that about Samuel.”
Bell accepted the criticism.
“This time, we control the entire chain.”
Claire looked at Sophie.
“I want her moved.”
“To another hospital?” Shah asked.
“Another room. Another floor. Somewhere not connected to her current chart.”
Bell agreed.
Before sunset Sophie was transferred under an alias to a secured pediatric room in another wing.
Only six people knew the room number.
Claire.
Daniel.
Eric.
Dr. Shah.
Agent Bell.
The charge nurse.
Sophie looked at the new name written on the whiteboard.
“Emily Carter?”
Claire shrugged.
“You don’t like it?”
“It sounds like someone who plays the flute.”
Daniel considered that.
“Maybe Emily Carter is dangerous.”
“No.”
“You’ve met her?”
“I can tell.”
They let the joke live for a few seconds.
At midnight, a hospital cybersecurity analyst discovered repeated attempts to locate Sophie’s room through internal systems.
The account belonged to a respiratory therapist who had been off duty for two days.
Compromised credentials.
The attempts stopped once the account was disabled.
At 2:13 a.m., another account searched her.
At 2:41, a third.
Someone was moving laterally through hospital access systems.
“They know she’s here,” Bell said.
“They just don’t know where.”
Claire looked at the dark hallway.
“They will.”
Bell did not answer.
The next morning the NorthStar shipment arrived.
Federal agents watched from hidden positions.
The driver delivered it normally and left.
No suspicious behavior.
The box was transferred to a controlled receiving room.
Inside were six cryogenic vials.
Dr. Shah reviewed the documentation.
Autologous engineered lymphocytes.
Claire frowned.
“Whose cells?”
Dr. Shah’s expression changed.
“They claim to be Sophie’s.”
“That’s impossible.”
“Unless someone collected them previously.”
Eric looked toward the old records.
“Facility 17.”
The vials were tested.
Preliminary matching confirmed Sophie’s DNA.
Her own cells had been harvested without her parents knowing.
Then altered.
Dr. Shah stared through the laboratory window at the container.
“What are they engineered to do?”
Tests began.
Hours later, the first answer came.
The cells targeted tissue expressing the synthetic receptor Samuel’s vector had created.
Daniel leaned forward.
“So those cells kill the tumor.”
“Potentially.”
Claire stared at Shah.
“This is the therapeutic phase.”
“Yes.”
The horrifying experiment had produced an actual targeted treatment.
A treatment built from Sophie’s own cells.
A treatment no ethical physician could administer without understanding its risks.
Sophie listened from her bed.
“So whoever did this made the cancer and the medicine?”
Dr. Shah hesitated.
“Possibly.”
“That’s stupid.”
Daniel nodded.
“Extremely.”
Sophie looked toward Claire.
“Can the medicine help me?”
“We don’t know yet.”
“But maybe?”
“Yes.”
Hope entered the room so quietly Claire almost resented it.
Later that afternoon, hospital receiving called.
Someone had arrived claiming to collect the shipment for pediatric oncology.
Bell’s team moved into position.
The man carried legitimate-looking identification.
His badge identified him as Dr. Aaron Pike.
Nobody at the hospital knew him.
Agents detained him.
Inside his briefcase they found a secure phone.
One contact.
No name.
Bell called the number from an isolated device.
It rang twice.
A man answered.
“Did you acquire the cells?”
Bell said nothing.
The man disconnected.
Tracing began.
The signal bounced through multiple relays.
Then one location appeared for less than three seconds.
A motel near the interstate.
Agents arrived twenty minutes later.
Room empty.
But inside they found discarded medical gloves, burner phones, a laptop drive, and a photograph.
The photograph showed Sophie entering school two years earlier.
On the back was handwritten text.
S.H.-10 ready for activation.
Below it was another line.
S.H.-11 identified.
Claire read it.
“There’s another child.”
Bell nodded.
Sophie was no longer the end of the experiment.
She was only the latest completed phase.
Click here to continue reading: PART 10: The Search for Subject Eleven Led Back to Sophie’s School, Where One Child Had Already Begun Showing the Same Symptoms
The Nurse Stopped Smiling Before She Closed the Door, and Claire Knew Sophie’s Routine Blood Test Had Found Something Wrong
Part 9 of 47
